Albuterol Inhalation Soln 0.5% Rx
Generic Name and Formulations:
Albuterol (as sulfate) 0.5%.
Various generic manufacturers
Indications for Albuterol Inhalation Soln 0.5%:
By nebulizer: 2.5mg (0.5mL of 0.5% diluted to 3mL with sterile normal saline, or 3mL of 0.083%) 3–4 times daily.
Use other forms.
Avoid excessive use. Sensitivity to sympathomimetics. Discontinue if paradoxical bronchospasm or cardiovascular effects occur. Cardiovascular disease (eg, coronary insufficiency, arrhythmias, hypertension). Diabetes. Hyperthyroidism. Seizure disorders. Reevaluate periodically. Elderly. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.
Avoid MAOIs, tricyclics within 14 days (increased cardiovascular effects). Oral sympathomimetics: not recommended. Antagonized by β-blockers. Monitor digoxin. Caution with other drugs that may lower serum potassium (eg, diuretics).
Tremor, nervousness, headache, dizziness, hyperactivity, insomnia, weakness, tachycardia, epistaxis, hypokalemia, throat irritation (inh), paradoxical bronchospasm; immediate hypersensitivity reactions (eg, rash, urticaria, angioedema).
Formerly known under the brand names Proventil (aerosol, soln, nebules), Ventolin (aerosol, soln, syrup).
Neurology Advisor Articles
- Case Study Report: Herbal Supplement Kratom Associated With Neonatal Abstinence Syndrome
- Seizure Monitoring Smartwatch Cleared for Use in Children
- Steps to Facilitate Rapid Reperfusion to Improve Poststroke Outcomes
- Ocrelizumab Reduces Upper Extremity Disability Progression Risk in PPMS
- Cerebellar Stimulation May Help Improve Gait and Balance Recovery in Stroke
- Very Early Mobilization After Stroke Does Not Improve Survival Over Usual Care
- Alemtuzumab Linked to Clinical and MRI Disease Remission in Multiple Sclerosis
- Cognitive Decline Worsens With Memantine, ChEIs in Patients With Alzheimer's
- Cervical Dysfunction Needs Clarification to Identify Link With Headache
- Levodopa Inhalation Powder Approved for Parkinson Disease
- Risk for Conversion of MS Varies With Different Therapies
- Breakdown of Blood-Brain Barrier May Drive Dementia
- FDA: Food Inspections to Resume Despite Ongoing Funding Lapse
- First Generic Version of Sabril Tablets Gets FDA Approval
- Supine Positioning After Greater Occipital Nerve Block May Improve Outcomes